Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

A Research Consortium Under the Direction of Grünenthal Will Receive a Grant of €1.5 million From the European Fund for Regional Development and the Federal State of North Rhein-Westphalia


News provided by

Grunenthal Group

27 Sep, 2016, 09:40 GMT

Share this article

Share toX

Share this article

Share toX

AACHEN, Germany, September 27, 2016 /PRNewswire/ --

  • Research grant awarded by Leitmarktwettbewerb LifeSciences.NRW to improve the development of new analgesic drugs 
  • The consortium members, founded and led by Grünenthal, are from the University Hospitals of Cologne and Bonn, and a specialist scientific company, Life & Brain 

The LifeSciences.NRW called for consortia of small and medium-sized companies and academic groups within North Rhein-Westphalia to compete in making proposals for developing solutions to solve current challenges within the field of biomedical sciences. Of the 51 submissions, the project of the consortium under the direction of Grünenthal was also considered worthy of funding. This proposal, entitled NeuRoWeg, was developed together with the University Hospitals in Cologne and Bonn, and a small specialist company, Life & Brain in Bonn, and will be supported with a grant of €1.5 million over the next three years. The aim is to improve the treatment of patients suffering from neuropathic pain, as this is only inadequately managed with currently available therapeutic agents. 

The € 1.5 million funding by the EU and the State of NRW will be used to support research into the molecular basis of neuropathic pain, and to develop novel test systems which will allow the efficacy of new analgesics for patients to be assessed more accurately and rapidly. This is reflected in the title of the NeuRoWeg project, "Innovative test systems for identifying curative analgesics with reliable efficacy in patients".

Neuropathic pain arises as a result of nerve injury caused by diseases such as diabetes, or by chemotherapy, or by accidents or surgery. It is suffered by approximately 7% - 10% of the general population[1], a very large number of people, and its incidence increases with age, especially in women.

Dr. Klaus-Dieter Langner, Chief Scientific Officer of Grünenthal, said, "I am looking forward to the results of this research project. I am also delighted that with the University Hospitals of Cologne and of Bonn, and with Life & Brain, we will have excellent partners within NRW at our side to jointly improve the prospects for developing better drug therapies for patients suffering from neuropathic pain."

Dr. Gregor Bahrenberg, the NeuRoWeg project coordinator and Laboratory Head at Grünenthal, added, "We continually strive to identify novel test systems with which we can more reliably and more rapidly characterize whether new drugs will be effective in humans. In order to achieve this, we want to collaborate with our partners to establish innovative assays employing stem cells derived from human skin or blood cells to advance the means for identifying novel pain medications which can cure patients. To this end, we will combine the expertise of renowned specialists with cutting-edge technologies.

"The ultimate aim is to predict the efficacy of new drugs in order to select the most suitable of the many research compounds for clinical development."

Dr. Petra Bloms-Funke is Head of the Department of Medical Intelligence and Innovation Partnerships and responsible for the acquisition of non-dilutive research funding for Grünenthal Innovation, the Research and Development Unit. She adds: "Our cooperative project NeuRoWeg will enhance our understanding of pain as a disease and how to cure it. A key problem in the development of new medicines is the poor ability of currently available test systems to predict efficacy in patients. This can lead to high failure rates during clinical development. We anticipate a considerable improvement with the highly innovative test systems we have planned. The consortium was founded because the success of this highly complex project will require coordinated contributions from highly specialized experts from different areas. Together we can advance and accelerate the development of new and effective pain medications, and make them available to patients more quickly than possible today. We are greatly looking forward to this inter-disciplinary collaboration."

Consortium Research Project 

Under the direction of Grünenthal, the University Hospital Cologne, the University Hospital Bonn, and the company Life & Brain in Bonn will each contribute their respective expertise to improve the development of new and effective drugs:

  • Grünenthal, Aachen (Dr. Petra Bloms-Funke, Dr. Gregor Bahrenberg) - emergence and therapy of neuropathic pain; characterization of specific target proteins in cells (pain targets); identification and selection of new drugs
  • University Hospital Bonn (Prof. Oliver Brüstle, Dr. Michael Peitz) - generation and differentiation of stem cells for therapeutic use in the treatment of and research into neurological disorders
  • Life & Brain, Bonn (Prof. Oliver Brüstle, Dipl. Biol. Simone Haupt) - application of stem cell technologies for the development of predictive biological test systems
  • University Hospital Cologne (Prof. Tim Hucho) - application of a special microscope technology, the so-called High Content Screening procedure, to investigate pain mechanisms and drug effects in pain cells

About the funding of bio-medical research and development in North Rhein-Westphalia with resources from the EU and of the Federal State of NRW 

The Federal State of North Rhein-Westphalia (NRW) initiated the Leitmarktwettbewerb LifeSciences.NRW, a funding competition, in 2015 to develop solutions to challenges in the field of health and well-being for our aging population. This initiative offers funding opportunities for groups of small and medium-sized enterprises, academic institutions and pharmaceutical companies in North Rhein-Westphalia, for innovative projects in research and development with resources provided by the EU and the State of North Rhein-Westphalia. By supporting innovation, the State of North Rhein-Westphalia wishes to secure sustainable growth and employment opportunities, and increase its international visibility as a leading location for Life Sciences.

About Grünenthal 

The Grünenthal Group is an independent, family-owned, international research-based pharmaceutical company headquartered in Aachen, Germany. We are an entrepreneurial specialist delivering true benefits to patients. By sustainably investing in research and development above the industrial average, we are committing to innovation in order to treat unmet medical needs and bring value-adding products to markets. Grünenthal is a fully integrated research & development company with a long track record of bringing innovative pain treatments and state-of-the-art technologies to patients.

Altogether, the Grünenthal Group is present in 32 countries with affiliates in Europe, Latin America and the US. Grünenthal products are sold in more than 155 countries and approx. 5,400 employees are working for the Grünenthal Group worldwide. In 2015, Grünenthal achieved revenues of € 1.2 bn. More information: http://www.grunenthal.com.

Literature 

1: van Hecke O. et al, Neuropathic pain in the general population: a systematic review of epidemiological studies. Pain. 2014 Apr;155(4):654-62

Contact: Steffen Fritzsche, Head Corporate Communications
Tel.: +49-241-569-1335, Fax.: +49-241-569-51335, steffen.fritzsche@grunenthal.com

Grünenthal GmbH, 52099 Aachen, Germany, http://www.grunenthal.com

Modal title

Also from this source

Maren Thurow starts as new Head Global Communications at Grünenthal

Maren Thurow has today assumed the role of Vice President and Head Global Communications at Grünenthal. She succeeds Florian Dieckmann, who has...

More Releases From This Source

Explore

Health Care & Hospitals

Health Care & Hospitals

Medical Pharmaceuticals

Medical Pharmaceuticals

Pharmaceuticals

Pharmaceuticals

New Products & Services

New Products & Services

News Releases in Similar Topics

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.